{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:06:54Z","timestamp":1790089614284,"version":"4.0.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"University Health Network Laboratory Medicine Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Somatic hypermutation at immunoglobulin heavy chain variable (IGHV) genes, an established prognostic and predictive biomarker for chronic lymphocytic leukemia (CLL), is assessed by gene sequencing. We developed a single methylation-specific droplet digital polymerase chain reaction (methyl-ddPCR) to predict IGHV status in patients with CLL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The CLL methylation array and IGHV data from the International Cancer Genome Consortium (ICGC) were used for biomarker discovery. Top-ranked candidate regions were manually screened for PCR primer and probe binding sites. A single methyl-ddPCR was evaluated on an internal cohort of CLLs with mutated (M), unmutated (U), and inconclusive IGHV results originally determined by next-generation sequencing (NGS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Analysis of ICGC data identified array probe cg23844018 as a candidate for the PCR. The corresponding CpG site showed high methylation levels in U-CLL and lower levels in M-CLL. On the internal cohort, a single optimal cutoff correctly classified 104 of 115 U- and M-CLLs (90.4%; area under the curve\u2005=\u20050.96). The PCR data correlated with some prognostic fluorescence in situ hybridization and CLL subset groupings. Limited analysis suggests that the PCR may be able to stratify some patients with CLL who have inconclusive results on IGHV NGS testing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The methyl-ddPCR showed high concordance with CLL IGHV status in an internal cohort.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqaf075","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T07:48:20Z","timestamp":1749887300000},"page":"474-483","source":"Crossref","is-referenced-by-count":3,"title":["Methylation-based droplet digital polymerase chain reaction shows high concordance with chronic lymphocytic leukemia <i>IGHV<\/i> somatic mutation status"],"prefix":"10.1093","volume":"164","author":[{"given":"Peter","family":"Sabatini","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine & Pathobiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Genome Diagnostics, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Advanced Molecular Diagnostics Laboratory, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Boruvka","sequence":"additional","affiliation":[{"name":"Advanced Molecular Diagnostics Laboratory, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Sean","family":"Kim","sequence":"additional","affiliation":[{"name":"Advanced Molecular Diagnostics Laboratory, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Feilotter","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine & Pathobiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Genome Diagnostics, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Advanced Molecular Diagnostics Laboratory, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Stockley","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine & Pathobiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Genome Diagnostics, University Health Network , Toronto, Ontario ,","place":["Canada"]},{"name":"Advanced Molecular Diagnostics Laboratory, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Princess Margaret Cancer Centre, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3825-0577","authenticated-orcid":false,"given":"Daniel","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine & Pathobiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Hematopathology and Transfusion Medicine, Laboratory Medicine Program, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2025091004265701800_CIT0001","author":"SEER","year":"2024"},{"key":"2025091004265701800_CIT0002","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1038\/s41375-022-01604-2","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL","volume":"36","author":"Agathangelidis","year":"2022","journal-title":"Leukemia."},{"key":"2025091004265701800_CIT0003","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood."},{"key":"2025091004265701800_CIT0004","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood."},{"key":"2025091004265701800_CIT0005","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood."},{"key":"2025091004265701800_CIT0006","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood."},{"key":"2025091004265701800_CIT0007","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol."},{"key":"2025091004265701800_CIT0008","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"J Clin Oncol."},{"key":"2025091004265701800_CIT0009","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1182\/blood.2019004492","article-title":"Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax","volume":"135","author":"Tausch","year":"2020","journal-title":"Blood."},{"key":"2025091004265701800_CIT0010","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"key":"2025091004265701800_CIT0011","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"Ascend: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol."},{"key":"2025091004265701800_CIT0012","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med."},{"key":"2025091004265701800_CIT0013","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet."},{"key":"2025091004265701800_CIT0014","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood."},{"key":"2025091004265701800_CIT0015","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/ng.2443","article-title":"Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia","volume":"44","author":"Kulis","year":"2012","journal-title":"Nat Genet."},{"key":"2025091004265701800_CIT0016","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/ng.3488","article-title":"DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia","volume":"48","author":"Oakes","year":"2016","journal-title":"Nat Genet."},{"key":"2025091004265701800_CIT0017","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1182\/blood.2020008311","article-title":"IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics","volume":"137","author":"Nadeu","year":"2021","journal-title":"Blood."},{"key":"2025091004265701800_CIT0018","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13073-015-0225-4","article-title":"Many obesity-associated SNPs strongly associate with DNA methylation changes at proximal promoters and enhancers","volume":"7","author":"Voisin","year":"2015","journal-title":"Genome Med."},{"key":"2025091004265701800_CIT0019","doi-asserted-by":"publisher","first-page":"e41361","DOI":"10.1371\/journal.pone.0041361","article-title":"Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility","volume":"7","author":"Reinius","year":"2012","journal-title":"PLoS One."},{"key":"2025091004265701800_CIT0020","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med."},{"key":"2025091004265701800_CIT0021","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature."},{"key":"2025091004265701800_CIT0022","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1093\/bioinformatics\/bti623","article-title":"ROCR: visualizing classifier performance in R","volume":"21","author":"Sing","year":"2005","journal-title":"Bioinformatics."},{"key":"2025091004265701800_CIT0023","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2024"},{"key":"2025091004265701800_CIT0024","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/s41379-020-0547-7","article-title":"Minimalist approaches to cancer tissue-of-origin classification by DNA methylation","volume":"33","author":"Xia","year":"2020","journal-title":"Mod Pathol."},{"key":"2025091004265701800_CIT0025","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/15592294.2018.1448679","article-title":"Droplet digital PCR is an accurate method to assess methylation status on FFPE samples","volume":"13","author":"Van Wesenbeeck","year":"2018","journal-title":"Epigenetics."},{"key":"2025091004265701800_CIT0026","doi-asserted-by":"publisher","first-page":"100145","DOI":"10.1016\/j.labinv.2023.100145","article-title":"Distinguishing gastric\/esophageal adenocarcinoma from pancreatic adenocarcinoma using methylation-based droplet digital PCR","volume":"103","author":"Xia","year":"2023","journal-title":"Lab Invest J Tech Methods Pathol."},{"key":"2025091004265701800_CIT0027","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/bioinformatics\/18.11.1427","article-title":"MethPrimer: designing primers for methylation PCRs","volume":"18","author":"Li","year":"2002","journal-title":"Bioinformatics."},{"key":"2025091004265701800_CIT0028","author":"Therneau","year":"2024"},{"key":"2025091004265701800_CIT0029","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/gb-2013-14-10-r115","article-title":"DNA methylation age of human tissues and cell types","volume":"14","author":"Horvath","year":"2013","journal-title":"Genome Biol."},{"key":"2025091004265701800_CIT0030","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/j.jmoldx.2021.09.002","article-title":"DNA methylation-based classification of small B-cell lymphomas: a proof-of-principle study","volume":"23","author":"Xia","year":"2021","journal-title":"J Mol Diagn."},{"key":"2025091004265701800_CIT0031","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/leu.2014.252","article-title":"A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact","volume":"29","author":"Queir\u00f3s","year":"2015","journal-title":"Leukemia."},{"key":"2025091004265701800_CIT0032","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1182\/blood.2019000490","article-title":"Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia","volume":"134","author":"Giacopelli","year":"2019","journal-title":"Blood."},{"key":"2025091004265701800_CIT0033","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1182\/blood.2023022180","article-title":"Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature","volume":"143","author":"Abdelbaky","year":"2024","journal-title":"Blood."},{"key":"2025091004265701800_CIT0034","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.1073\/pnas.1913810117","article-title":"IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling","volume":"117","author":"Maity","year":"2020","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2025091004265701800_CIT0035","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/bjh.18465","article-title":"Integrative epigenomics in chronic lymphocytic leukaemia: biological insights and clinical applications","volume":"200","author":"Kulis","year":"2023","journal-title":"Br J Haematol."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/164\/3\/474\/63886183\/aqaf075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/164\/3\/474\/63886183\/aqaf075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T08:27:04Z","timestamp":1757492824000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/164\/3\/474\/8218262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,7,30]]},"published-print":{"date-parts":[[2025,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqaf075","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,30]]}}}